Document is current
Any future updates will be listed below
-
Authors
Okamura, Akihiko
Watanabe, Masayuki
Okui, Jun
Matsuda, Satoru
Takemura, Ryo
Kawakubo, Hirofumi
Takeuchi, Hiroya
Muto, Manabu
Kakeji, Yoshihiro
Kitagawa, Yuko
Doki, Yuichiro
- License Information
-
More Information
Article History
Received: 14 November 2022
Accepted: 15 November 2022
First Online: 20 December 2022
Disclosure
: Yuko Kitagawa had relevant financial activities outside this study for Chugai Pharmaceutical Co., Ltd; Taiho Pharmaceutical Co., Ltd; Yakult Honsha Co. Ltd; Asahi Kasei Pharma Corporation Otsuka; Pharmaceutical Co., Ltd; Takeda Pharmaceutical Co., Ltd; Ono Pharmaceutical Co., Ltd; Tsumura & Co.; Kyouwa Hakkou Kirin Co., Ltd; EA Pharma Co., Ltd; Medicon Inc; Kaken Pharmaceutical Co. Ltd;. Eisai Co., Ltd; Otsuka Pharmaceutical Factory Inc.; Teijin Pharma Limited; Nihon Pharmaceutical Co., Ltd; Nippon Covidien Inc; Shionogi & Co., Ltd; Ethicon, Inc. Olympus Corporation Bristol-Myers; Squibb K. K.; AstraZeneca K. K. MSD; K. K. Smith & Nephew; K. K. ASKA Pharmaceutical Co., Ltd; Miyarisan Pharmaceutical Co. Ltd.
